2023 ABAI Continuous Assessment Program Literature Review - February-July

This literature review course, originally presented as part of the 2023 AAAAI Annual Meeting, will help to prepare ABAI diplomates to participate in the Continuous Assessment Program (CAP). The course will include reviews of the journal articles selected for the January-June 2021 term of the CAP to help develop greater familiarity with the key concepts included in them. 

The five presentations cover a range of critical journal articles in the following topic areas:

  • Food and Drug Allergy/Hypersensitivity Reactions and Eosinophilic or Gastrointestinal Disorders
  • Conditions of the Head/Neck and Lungs
  • Dermatologic Conditions and Anaphylaxis 
  • Immune Hypersensitivity Disorders and Immunodeficiencies
  • Emerging National Health Priorities

Click the Program tab to access the full list of articles, with links. Please note that all CAP articles can be accessed through the ABAI web portal.

Target Audience

  • Allergist/Immunologists participating in continuous certification with the American Board of Allergy & Immunology
  • Allied health providers working in allergy/immunology settings
  • Allergy/Immunology Fellows-in-Training preparing for initial certification
  • Other healthcare providers with an interest in allergy/immunology

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate recently published research relevant to the practice of allergy/immunology
Summary
Available credit: 
  • 2.00 Attendance
    Attendance credit.
  • 2.00 CME
    CME credit.
Course opens: 
03/31/2023
Course expires: 
07/31/2023
Cost:
$0.00
Rating: 
0

All CAP articles are listed, below.
Articles can be accessed through the ABAI web portal.
 

CAP 2023 – Block 1 Article-based Reference List

A1 Head/Neck
 Borish L, et al. Yardstick for the medical management of chronic rhinosinusitis. Annals of Allergy, Asthma & Immunology. 2022;128(2):118-128. https://doi.org/10.1016/doi:10.1016/j.anai.2021.10.014
 Mullol J, et al. Olfactory outcomes with dupilumab in chronic rhinosinusitis with nasal polyps. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(4):1086-1095.e5. https://doi.org/10.1016/j.jaip.2021.09.037
 Oykhman P, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis. Journal of Allergy and Clinical Immunology. 2022;149(4):1286-1295. https://doi.org/10.1016/j.jaci.2021.09.009
 Smith SS, Kim R, Douglas R. Is there a role for antibiotics in the treatment of chronic rhinosinusitis? Journal of Allergy and Clinical Immunology. 2022;149(5):1504-1512. https://doi.org/10.1016/j.jaci.2022.02.004

A2 Dermatologic
 Baeza ML, et al. Angioedema due to acquired deficiency of C1-inhibitor: A cohort study in Spain and a comparison with other series. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(4):1020-1028. https://doi.org/10.1016/j.jaip.2021.11.018
 Johansen JD, et al. Novel insights into contact dermatitis. Journal of Allergy and Clinical Immunology. 2022;149(4):1162-1171. https://doi.org/10.1016/j.jaci.2022.02.002
 Khan DA, et al. What’s new in the treatment of urticaria and angioedema. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(6):2170-2184. https://doi.org/10.1016/j.jaip.2021.03.012
 Singh AM, et al. Atopic dermatitis and food allergy: Best practices and knowledge gaps—a work group report from the AAAAI Allergic Skin Diseases Committee and Leadership Institute Project. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(3):697-706. https://doi.org/10.1016/j.jaip.2021.12.037

A3 Lung
 Brennan V, et al. The contribution of oral and inhaled glucocorticoids to adrenal insufficiency in asthma. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(10): 2614-2623. https://doi.org/10.1016/j.jaip.2022.05.031
 Hurrell BP, et al. Cannabinoid receptor 2 engagement promotes group 2 innate lymphoid cell expansion and enhances airway hyperreactivity. Journal of Allergy and Clinical Immunology. 2022;149(5):1628-1642.e10. https://doi.org/10.1016/j.jaci.2021.09.037
 Wilson K, et al. The association between duration of breastfeeding and childhood asthma outcomes. Annals of Allergy, Asthma & Immunology. 2022;129(2):205-211. https://doi.org/10.1016/j.anai.2022.04.034

A4 Food and Drug Allergy/Hypersensitivity Reactions
 González-Delgado P, et al. Food protein–induced enterocolitis syndrome in adulthood: Clinical characteristics, prognosis, and risk factors. The Journal of Allergy and Clinical Immunology: In Practice. 2022. https://doi.org/10.1016/j.jaip.2022.05.006
 Li L, et al. Safety, outcomes, and recommendations for two-step outpatient nonsteroidal anti-inflammatory drug challenges. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(5):1286-1292.e2. https://doi.org/10.1016/j.jaip.2021.11.006
 Peters RL, et al. The natural history of peanut and egg allergy in children up to age 6 years in the HealthNuts population-based longitudinal study. Journal of Allergy and Clinical Immunology. 2022;150(3):657-665.E13. https://doi.org/10.1016/j.jaci.2022.04.008
 van der Poorten M-LM, et al. Reliability of early and late testing for suspected perioperative hypersensitivity. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(4):1057-1062.e2. https://doi.org/10.1016/j.jaip.2021.10.066

A5 Anaphylaxis
 Carra S, et al. Anaphylaxis and pregnancy: A systematic review and call for Public Health Actions. The Journal of Allergy and Clinical Immunology: In Practice. 2021;9(12):4270-4278. https://doi.org/10.1016/j.jaip.2021.07.046
 Cuevas-Bravo C, et al. Kounis syndrome. Annals of Allergy, Asthma & Immunology. 2022;129(2):252-253. https://doi.org/10.1016/j.anai.2022.05.021
 Gotlib J, et al. Proposed European Competence Network on mastocytosis—american initiative in mast cell diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(8):2025-2038.E1. https://doi.org/10.1016/j.jaip.2022.05.034
 Meir LR, et al. Anaphylaxis among elderly emergency department patients in a large health system in New York. Annals of Allergy, Asthma & Immunology. 2022;129(1):63-70.e3. https://doi.org/10.1016/j.anai.2022.03.020

B1 Immune Hypersensitivity Disorders
 Fijen LM, et al. Inhibition of prekallikrein for hereditary angioedema. New England Journal of Medicine. 2022;386(11):1026-1033. https://doi.org/10.1056/nejmoa2109329
 Requena G, et al. Clinical profile and treatment in hypereosinophilic syndrome variants: A pragmatic review. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(8):2125-2134. https://doi.org/10.1016/j.jaip.2022.03.034
 Schuppan D, et al. A randomized trial of a transglutaminase 2 inhibitor for celiac disease. New England Journal of Medicine. 2021;385(1):35-45. https://doi.org/10.1056/nejmoa2032441

B2 Immunodeficiencies
 Barmettler S, et al. Response to severe acute respiratory syndrome coronavirus 2 initial series and additional dose vaccine in patients with predominant antibody deficiency. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(6):1622-1634.e4. https://doi.org/10.1016/j.jaip.2022.03.017
 Eddens T, et al. Trends in pediatric primary immunodeficiency: Incidence, utilization, transplantation, and mortality. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(1):286-296.e3. https://doi.org/10.1016/j.jaip.2021.10.033
 LaBere B, et al. Chronic granulomatous disease with inflammatory bowel disease: Clinical presentation, treatment, and outcomes from the USIDNET Registry. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(5):1325-1333.e5. https://doi.org/10.1016/j.jaip.2021.12.035
 Lee TK, Gereige JD, Maglione PJ. State-of-the-art diagnostic evaluation of common variable immunodeficiency. Annals of Allergy, Asthma & Immunology. 2021;127(1):19-27. https://doi.org/10.1016/j.anai.2021.03.005

B3 Eosinophilic or Gastrointestinal Disorders
 Chen MM, et al. An international, retrospective study of off-label biologic use in the treatment of hypereosinophilic syndromes. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(5):1217-1228.e3. https://doi.org/10.1016/j.jaip.2022.02.006
 Dellon ES, Simon D, Wechsler ME. Controversies in allergy: The potential role of biologics as first-line therapy in eosinophilic disorders. The Journal of Allergy and Clinical Immunology: In Practice. 2022;10(5):1169-1176. https://doi.org/10.1016/j.jaip.2022.01.043
 Leiferman KM, Peters MS. Eosinophil-related disease and the skin. The Journal of Allergy and Clinical Immunology: In Practice. 2018;6(5):1462-1482.e6. https://doi.org/10.1016/j.jaip.2018.06.002
 Muir AB, et al. Esophageal remodeling in eosinophilic esophagitis: Relationships to luminal captured biomarkers of inflammation and Periostin. Journal of Allergy and Clinical Immunology. 2022;150(3):649-656.E5. https://doi.org/10.1016/j.jaci.2022.03.022

C Emerging National Health Priorities
 Biagini JM, et al. Longitudinal atopic dermatitis endotypes: An atopic march paradigm that includes Black Children. Journal of Allergy and Clinical Immunology. 2022;149(5):1702-1710.E4. https://doi.org/10.1016/j.jaci.2021.09.036
 Israel E, et al. Reliever-triggered inhaled glucocorticoid in black and Latinx adults with asthma. New England Journal of Medicine. 2022;386(16):1505-1518. https://doi.org/10.1056/nejmoa2118813
 Magnus MC, et al. Association of SARS-COV-2 vaccination during pregnancy with pregnancy outcomes. JAMA. 2022;327(15):1469-1477. https://doi.org/10.1001/jama.2022.3271
 Sullivan DJ, et al. Early outpatient treatment for covid-19 with convalescent plasma. New England Journal of Medicine. 2022;386(18):1700-1711. https://doi.org/10.1056/nejmoa2119657

 

Planning Committee

Programmed by the 2022-2023 AAAAI Annual Meeting Program Committee
Committee member financial disclosures are available for review here

Faculty

Yamini Virkud, MD FAAAAI
University of North Carolina, Chapel Hill, NC
Relevant relationships: None

Anju T. Peters, MD MSCI  FAAAAI
Northwestern University Medical School, Chicago, IL
Relevant relationships: None

John Kelso, MD FAAAAI
Scripps Clinic, La Jolla, CA
Relevant relationships: None

Yasmin W. Khan, MD 
Vanderbilt University Medical Center, Nashville, TN
Relevant relationships: None

David R. Stukus, MD FAAAAI
Nationwide Children's Hospital, Columbus, OH
Relevant relationships: None

All relevant relationships disclosed by planners and faculty have been mitigated.

AAAAI Disclosure Policy

Pursuant to the Code of Ethics for the American Academy of Allergy, Asthma & Immunology (AAAAI) and the Standards for Commercial Support of Continuing Medical Education of the Accreditation Council for Continuing Medical Education, the AAAAI requires disclosure of certain information from faculty members of educational activities designated for CME credit by the AAAAI. Prior to the activity, planners and presenters are required to disclose all relationships that meet the following parameters:

  • Employment. Name of employer and job title.
  • Financial interests. All organizations, other than the employer, from which the faculty member or a member of his/her immediate family or household receives annual remuneration in any amount (including grants, honoraria and consulting fees).
  • Research interests. All organizations which support research projects for which the faculty member or member of his/her immediate family or household serves as an investigator.
  • Legal Consultation Services/Expert Witness Testimony: All topics on which the faculty member provided legal consultation and/or expert witness testimony during the previous calendar year.
  • Organizational interests: All organizations, other than the AAAAI, for which the faculty member holds volunteer positions.
  • Gifts. All organizations from which the faculty member or a member of his/her immediate family or household have received a gift of any amount in the last year.
  • Other interests. All interests of the faculty member or a member of his/her immediate family or household that would be judged by a majority of his/her peers to be more than casual and/or likely to impact his/her ability to exercise independent judgment. This includes any financial interest in or relationship with any manufacturer of a commercial product, and any financial interest or relationship with any organization that provides commercial support to AAAAI-sponsored educational activities.

The information disclosed by the speakers and planning committee was reviewed in accordance with the AAAAI Disclosure Policy. All potential conflicts of interest were resolved by the planners, faculty, and reviewers prior to their participation in the development of this activity.

 

Disclosure link: 
2023 AAAAI Annual Meeting Disclosures

Accreditation Statement
The American Academy of Allergy, Asthma and Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
The American Academy of Allergy, Asthma & Immunology designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAAAI Privacy Policy
To verify your participation in educational activities, you may be asked to provide your name, contact information, and/or other descriptors. The AAAAI will not release this information to outside entities. It may be used internally to inform you of other AAAAI educational activities. If you wish to have your information excluded from this process, please contact us at cme@aaaai.org.

Release date
Original release date: April 1, 2023. Valid for credit through July 31, 2023.

Questions
Activity-related questions should be directed to cme@aaaai.org.

Available Credit

  • 2.00 Attendance
    Attendance credit.
  • 2.00 CME
    CME credit.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

One of the two most recent versions of Chrome, Firefox, or Safari.

Internet Explorer is no longer supported.